BALTIMORE, March 7, 2013 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), a pioneer in conducting patient-specific analyses aimed at identifying genomic alterations in tumors, today announced a number of developments that will support its expanding business. The company licensed exclusive rights to Digital Karyotyping (DK), an important genome-mapping technology developed by the company's founders at Johns Hopkins University. PGDx also announced that it is expanding into new facilities and has made a number of key hires, including Genzyme Oncology executive Antony Newton as Chief Commercial Officer.
PGDx's co-founders include Chief Scientific Officer Dr. Victor Velculescu and Chief Medical Officer Dr. Luis Diaz , international leaders in cancer genetics and faculty members at the Johns Hopkins University School of Medicine, who were the first to perform genome-wide sequence analyses of human cancer. They and colleagues at Johns Hopkins, including Dr. Bert Vogelstein , a recent recipient of the Breakthrough Prize in Life Sciences for his work in colon cancer, established the company in response to requests from cancer researchers and clinicians for commercial access to their specialized genome-mapping services and analyses. PGDx has licensed rights from Johns Hopkins to proprietary methods based on next-generation sequencing, patented approaches to genetic analysis and proprietary data algorithms, and its scientists have deep expertise in the practical application of these technologies to the study of cancer genomics.
"At PGDx, we are fortunate to be able to bring the latest advances in cancer genomics such as Digital Karyotyping to cancer researchers and clinicians around the globe," said Antony Newton . "This is an exciting time
|SOURCE Personal Genome Diagnostics Inc.|
Copyright©2012 PR Newswire.
All rights reserved